Expatriate International Health Insurance news: Personalised treatments 'will be available in the future'

Expatriates with international health insurance and other individuals will be treated with personalised healthcare in the future, according to one expert.

Pharmacist Gino Martini, senior director at GlaxoSmithKline (GSK) Research and Development, claimed that medical professionals are constantly making breakthroughs.

New technologies will focus on "giving the right drug to the right patient at the right time", he explained, which will increase the impact of medicine while reducing adverse reactions.

However, he noted that the most effective personalised treatments would require a product for every individual.

This would be impossible for businesses as the global population is too large, the expert asserted.

Further advances will be seen in areas including oncology, diabetes, cholesterol, hypertension, cardiovascular health and metabolic disease, Mr Martini continued.

GSK is an international organisation based in the UK with offices in over 100 countries. It produces treatments for diseases such as asthma, digestive conditions, mental health problems, infections and cardiovascular issues.

Expatriate Group & Expatriate Healthcare are trading styles of Strategic Insurance Services Limited who is authorised and regulated by the Financial Conduct Authority (FCA). FCA Firm reference Number is 307133. Strategic Insurance Services Limited is authorised to carry on Regulated Activities in accordance with the permissions granted by the FCA under PART IV of the Financial Services and Markets ACT 2000.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptRead More